Loss of 1p36 heterozygosity commonly occurs with MYCN amplification in neuroblastoma tumors, and both are associated with an aggressive phenotype. Database searches identified five microRNAs that map to the commonly deleted region of 1p36 and we hypothesized that the loss of one or more of these microRNAs contributes to the malignant phenotype of MYCNamplified tumors. By bioinformatic analysis, we identified that three out of the five microRNAs target MYCN and of these miR-34a caused the most significant suppression of cell growth through increased apoptosis and decreased DNA synthesis in neuroblastoma cell lines with MYCN amplification. Quantitative RT-PCR showed that neuroblastoma tumors with 1p36 loss expressed lower level of miR-34a than those with normal copies of 1p36. Furthermore, we demonstrated that MYCN is a direct target of miR-34a. Finally, using a series of mRNA expression profiling experiments, we identified other potential direct targets of miR-34a, and pathway analysis demonstrated that miR-34a suppresses cell-cycle genes and induces several neural-related genes. This study demonstrates one important regulatory role of miR-34a in cell growth and MYCN suppression in neuroblastoma.
Introduction
Neuroblastoma (NB) is the most frequent extracranial childhood solid tumor. Prognosis of this disease varies from spontaneous regression to aggressive progression, depending on several known clinical parameters and genetic aberrations. Among these, MYCN amplification, found in 20-30% of NB tumors, was the first and is the only molecular marker currently used in clinic to stratify patients for therapy (Brodeur, 2003) . The MYCN oncogene encodes a transcription factor belonging to the MYC gene family, and is primarily expressed during normal developing embryos (Zimmerman et al., 1986) . MYCN is thought to be critical in the tumorigenesis of NB (Weiss et al., 1997) , as well as in normal brain and other neural development (Zindy et al., 2006) . Patients with MYCN amplification and older than 1 year have o30% chance of survival despite aggressive multimodal therapies including surgery, chemotherapy, radiation therapy and stem cell transplant. Elevated expression levels of the MYCN gene subsequent to amplification is thought to be critical for the aggressive behavior of MYCN-amplified NBs (Kohl et al., 1984) , but the mechanism of its oncogenic effect has not been determined.
Interestingly, loss of heterozygosity (LOH) of 1p36 (25-30% of NBs) is commonly found in NBs with MYCN amplification and is associated with poor outcome (Guo et al., 1999; Attiyeh et al., 2005; White et al., 2005) . As the loss of 1p36 was first reported in NB by Brodeur et al. (1977) , studies have identified the deletion of this region in many other human malignancies such as brain tumor (Hashimoto et al., 1995) , melanoma (Poetsch et al., 1998) , leukemia (Mori et al., 1998) , breast cancer (Bieche et al., 1998) and cervix cancer (Cheung et al., 2005) , suggesting the presence of tumor suppressor gene(s) in this region. Chromosomal transfer experiments support such a hypothesis, as NB cell lines transfected with 1p DNA showed neuronal differentiation and suppression of tumorigenicity (Bader et al., 1991) . Studies have been performed to delineate the smallest region of overlap (SRO) on 1p36 in NBs, and have identified a consensus region of loss between 1p36.2 and 1pter (Fong et al., 1989; White et al., 1995 White et al., , 2005 Hogarty et al., 2000; Maris et al., 2001; Chen et al., 2004; Mosse et al., 2005) . Although many genes including CHD5 (Thompson et al., 2003; Bagchi et al., 2007) , CAMTA1 (Barbashina et al., 2005; Henrich et al., 2006) , HKR3 (Maris et al., 1997) , Apo-3 (Eggert et al., 2002) , ENO1 (Ejeskar et al., 2005) , EXTL1 (Mathysen et al., 2004) , DFF45 (Abel et al., 2004) , p73 (Kong et al., 1999; Ozaki et al., 2005) and PITSLRE (Lahti et al., 1994) mapped to this consensus region have been implicated to have antitumorigenic effects, the identity of the single-causal tumor suppressor gene(s) on 1p36 remains elusive due to the similar effects of these genes on the behavior of NB cells.
Although most conventional genes encode proteins to carry out their biological functions, a recently discovered class of genes transcribing small noncoding RNAs, namely microRNAs, was found to be important in regulating normal development and physiology in plants and animals (Bartel and Bartel, 2003; Bartel, 2004) . Mature microRNAs are 20-22 nucleotide molecules that can regulate gene expression through RNA interference effecter complex (RISC)-mediated mRNA degradation and translational suppression by complementary pairing predominantly to the 3 0 -untranslated region (3 0 -UTR) of their targeted mRNAs (Ambros, 2004; Bartel, 2004 ). An increasing number of studies have demonstrated a perturbation of the normal expression patterns of microRNAs in many human cancers (Calin et al., 2002; Cimmino et al., 2005; Lu et al., 2005; Costinean et al., 2006) . Recently, a study by Welch et al. (2007) demonstrated that a microRNA located in 1p36, miR34a, induced apoptosis in NB cells, suggesting its important role in regulating cell growth and death. Several studies further demonstrated that p53 directly regulates the members of miR-34 family including miR34a, and miR-34 family members can mediate some of the p53 functions (Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 2007) .
In this study, we identified that among the five microRNAs mapping to 1p36 three are predicted to target MYCN, and miR-34a had the most growthsuppressing effect on the MYCN-amplified NB cells among these three microRNAs. In addition, we provide evidence that miR-34a can directly regulate the MYCN protein level by targeting its 3 0 -UTR. Furthermore, global gene expression profiles demonstrated suppression of cell-cycle genes and induction of neural genes in NB cells mediated by miR-34a. Therefore, our study reveals an important regulatory role of miR-34a in modulating MYCN activity in NB tumors.
Results
Biological effects of microRNAs on MYCN-amplified cell lines Due to the frequent association of 1p36 loss in NB tumors with MYCN amplification, we investigated if microRNAs mapping to this region may affect growth of NB cells with MYCN amplification. We first identified that five microRNAs map within the first 10 Mb on chromosome 1 short arm (1p36.22 to 1pter), which is commonly deleted in NB (Fong et al., 1989; White et al., 1995 White et al., , 2005 Hogarty et al., 2000; Maris et al., 2001; Chen et al., 2004; Mosse et al., 2005) , using the Sanger microRNA registry (http://microrna.sanger. ac.uk/sequences/index.shtml, Release 10.0) (Figure 1a ).
Of note, three of these (miR-200b, 429 and 34a) target the MYCN gene as predicted by computational analysis on the Sanger microRNA registry miRBase website. We thus investigated the effect on growth for these three microRNAs on IMR32 and LA-N-5 cell lines (both contain MYCN amplification). We found that exogenous miR-34a resulted in a significant reduction in cell growth compared to the mimic control for both the cell lines, whereas miR-200b and miR-429 had little or no effect (Figure 1b) . To further characterize miR-34a-mediated inhibition of cell growth, we first measured the cell death using 7-AAD staining (uptake in dead cells) at 48 h post-transfection (Figure 1c upper left) . IMR32 cells transfected with miR-34a had a 29% increase in cell death compared to those transfected with mimic control microRNA. Then, we investigated if the increased cell death was due to apoptosis using an antibody specific to the active form of caspase 3 in a flow cytometry analysis. The apoptosis rate doubled (213%) in miR-34a-transfected cells in comparison to the mimic control (Figure 1c upper right) . Finally, we measured the DNA synthesis using a bromodeoxyuridine (BrdU) incorporation assay ( Figure 1c , lower left) and demonstrated a modest reduction of BrdU incorporation in miR-34a-transfected cells by 27% compared to the mimic control. A summary of the percentage change for cell death, apoptosis and DNA synthesis of a representative experiment is shown in the lower right panel of Figure 1c . In addition, a cell-cycle analysis on IMR32 cells transfected with miR-34a also demonstrated increased apoptosis and suppressed percentage of cells in the S and G 2 /M phases (Supplementary Figure 1) . Therefore, exogenous miR-34a suppresses NB cell growth through both increasing apoptosis and decreasing DNA synthesis.
Neuroblastoma tumors with 1p36 deletion express less miR-34a
In order to examine if 1p36 deletion results in any change in the expression of miR-34a in primary NB tumors, we performed TaqMan real-time RT-PCR on a set of stage 4 primary human NB tumors, of which eight were with 1p36 LOH (seven of them are MYCN amplified) and eight were not amplified and did not demonstrate LOH of this region. Consistent with a previous study (Welch et al., 2007) , the level of miR-34a expression is lower in tumors with 1p36 deletion than in those with normal copy number (P ¼ 0.038) (Figure 2) . Therefore, we demonstrated that genomic 1p36 deletion has an impact on the miR-34a expression in NB tumors, and the association of low miR-34a expression with this deletion implies a possible role of this microRNA in NB tumors with MYCN amplification.
miR-34a directly targets the MYCN gene We next investigated if miR-34a directly targeted the MYCN gene. We first performed a western blot analysis on the total protein extracts from IMR32 and LA-N-5 cells transfected with miR-34a 48 h after transfection (Figure 3a, left panel) . Quantification of the MYCN immunobands on the western blot demonstrated that miR-34a caused an 80 or 95% reduction of MYCN protein in both IMR32 and LA-N-5 cells, respectively, after normalization by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Figure 3a , right panel).
We found by bioinformatic analysis and search of the Sanger microRNA registry that the MYCN 3 0 -UTR contains two target sequences for the miR-34a at positions 10 and 567 (Figure 3b ) (http://microrna. sanger.ac.uk/cgi-bin/targets/v5/detail_view.pl?transcript _id ¼ ENST00000281043). In order to test if miR-34a directly targets MYCN gene, we cloned the entire wildtype3 0 -UTR of the MYCN gene into a luciferase reporter vector. Due to the endogenous expression of miR-34a in IMR32 and LA-N-5 cells, we transfected the resulting reporter construct (pMIR-MYCN-WT) into SK-N-AS cell, a NB cell line that does not express miR34a (data not shown), along with miR-34a or a mimic control microRNA. The luciferase activity assays at 24 h post-transfection demonstrated that miR-34a suppressed luciferase reporter activity by 50% (Figure 3c ). To demonstrate the specificity of miR-34a directly targeting the MYCN gene, we generated mutation reporter constructs of each of the two predicted miR34a binding sites on the MYCN 3 0 -UTR (pMIR-MYCN-MT1&2) and a double mutation construct of both the sites (pMIR-MYCN-MT1&2) (Figure 3b ), and examined if these mutations would eliminate the suppression of the luciferase reporter activity. Figure 3c demonstrates that a mutation on either one of the predicted miR-34a binding sites attenuated the suppression of miR-34a on the luciferase activity, whereas mutations on both the sites abolished the suppression of luciferase reporter by miR-34a. These experiments demonstrate that miR-34a directly targets the MYCN gene through its 3 0 -UTR, and both the binding sites of miR-34a on MYCN 3 0 -UTR are required for the suppressive activity of miR-34a on MYCN. , miR-429 and mimic control, the growth was monitored using WST-1 assays for 4 days. The optical densities (OD) at 450 nm corrected by OD 650 nm were plotted over time after background subtraction of the readings from the mediaonly wells. miR-34a clearly suppressed the growth of both IMR32 and LA-N-5, but miR-200b and -429 had little or no effect. (c) A representative flow cytometry experiment shows miR-34a inducing apoptosis and suppression of DNA synthesis. Flow cytometry was used to study cell death (7-AAD staining), apoptosis (caspase 3 staining) and DNA synthesis (bromodeoxyuridine (BrdU) staining) in IMR32 cells at 48 h after transfection. Blue: mimic control transfection; Red: miR-34a transfection. The bar graph summarizes the results of flow cytometry. Cell death and apoptosis were increased by 29 and 113%, respectively, whereas DNA synthesis was suppressed by 27% in the miR-34a-transfected cells.
Pathway analysis of mRNA global gene expression alterations in IMR32 cells transfected with miR-34a
We next investigated the pathways regulated by miR34a. Because microRNAs had been demonstrated to regulate mRNA levels (Ambros, 2004; Bartel, 2004; Lim et al., 2005) , we performed global gene expression profiling on miR-34a-transfected cells at 48 h using Affymetrix U133 plus 2.0 chips. We used gene set enrichment analysis (GSEA), which is a computational method that determines whether a priorly defined set of genes or pathways shows statistically significant enrichment in the most altered genes (Subramanian et al., 2005) . We found that miR-34a significantly altered nine annotated cellular functions (Po0.01 and FDRo0.05) including seven associated with the downregulated genes and two with the upregulated genes by miR-34a ( Figure 4a ). Interestingly, the downregulated genes have functions in cell proliferation (DNA replication, RNA transcription and mRNA processing, cell cycle, and translation), whereas the upregulated genes belonged to G-protein coupled receptors, which are involved in neuronal signaling (Figure 4a and Supplementary Table 1 ). Figure 4b shows an example of GSEA enrichment plot for one of the nine function sets (CELL_CYCLE). Therefore, changes of global gene expression profile are consistent with what we observed at the cellular level, and the global gene expression profiling demonstrated that miR-34a inhibits growth and induces a neuronal phenotype in IMR32 cells.
Identification of other direct targets of miR-34a
In order to delineate the direct targets of miR-34a from those genes controlled by MYCN, we induced MYCN expression in another NB cell line, MYCN-3, using a previously published inducible expression construct (Slack et al., 2005) and performed gene expression profiling at 12 h after induction. Western blot analysis confirmed induction of MYCN protein expression (Figure 5a ). The numbers of differentially expressed genes mediated by miR-34a or MYCN are shown in a Venn diagram (Figure 5b) . Genes in group A (suppressed by miR-34a only) are the potential direct targets for miR-34a, as they are not upregulated by MYCN induction, whereas genes in group B are potential indirect targets mediated by changes of the MYCN level ( Figure 5b ). In order to validate this approach, we examined if there is enrichment of miR-34a target sequences in the 3 0 -UTR of the genes in these three gene groups. A search for sequence complementary to the miR-34a seed sequence (binding site) in 3 0 -UTRs in all groups showed that the group A genes are significantly enriched for the complementary sequence of the miR34a seed (P ¼ 2.12 Â 10 Table 2 ). When we searched the functional annotation for these genes in a database for annotation, visualization, and integrated discovery (DAVID; http://www.david.niaid. nih.gov) (Dennis et al., 2003) , and used a cutoff of Po0.01 for functional annotation enrichment, we found that they have diverse functions from primary metabolism to alternative splicing (Supplementary Table 3) . Interestingly, one gene ontology term of phosphorylation consists of 23 genes including EPB41, CDK6, PDGFRA, PDGFRB, MAP2K1, KIT and so on, which are important molecules for cell signaling and proliferation. Downregulation of these genes by miR-34a is consistent with the observation of miR-34a-induced growth inhibition in NB cells.
Using a similar strategy, we examined if there is overrepresentation of E-box sequences, MYCN binding sites, in a 2.5 kb promoter region of all gene groups. We found there is a significant enrichment for E-box sequences in group C, but not in A or B (Figure 5c ) (Po0.01). A list of genes containing E-box sequences is provided in the Supplementary Table 4. Therefore, these sequence enrichment analyses validate our approach to identify the direct targets of miR-34a, and the genes in group A represent potential direct targets of miR-34a, which requires further confirmatory studies.
Discussion
MicroRNAs have been demonstrated to be important in development and maintenance of normal cellular function, and alteration in expression of microRNAs can result in human cancers (Calin et al., 2002; He et al., 2005; Iorio et al., 2005; Costinean et al., 2006) . Due to the frequent association of 1p36 loss in MYCNamplified NB tumors, we examined the functional role of microRNAs mapping to the commonly deleted region within the first 10 Mb of chromosome 1 (1p36.22 to 1pter). Five known microRNAs were mapped to this region, and three of them (miR-200b, 429 and 34a) are predicted to target the MYCN gene. Introduction of these three microRNAs into NB cells with MYCN amplification showed that miR-34a, but not miR-200b or 429, can significantly suppress cell growth. We demonstrated that miR-34a directly inhibits MYCN protein by targeting the 3 0 -UTR of the MYCN gene. Gene expression profiling confirmed that miR-34a can suppress cell-cycle genes and induces a neural phenotype. These results resemble the effect of transferring 1p DNA material into NB cell lines, which also resulted in neuronal differentiation and apoptosis (Bader et al., 1991) .
MYCN amplification is the only molecular marker currently used in clinic to predict poor outcome for NB patients. The oncogenic function of MYCN and its homolog MYC has been recognized in several human malignancies including NB, Burkitts lymphoma, colon cancer, breast cancer, lung cancer and so on (Nesbit et al., 1999) . The MYC gene has been demonstrated to be important in both cell proliferation and apoptosis (Schwab and Bishop, 1988; Evan et al., 1992) . Here, we showed that miR-34a mediated inhibition of NB growth as a result of induction of apoptosis and modest suppression of DNA synthesis. Similar findings have been reported when MYCN is suppressed in MYCNamplified cell lines (Kang et al., 2006; Nara et al., 2007; Woo et al., 2007) . Therefore, some of the inhibitory effects of miR-34a on cell growth shown in this study are likely mediated by the suppression of MYCN protein. In addition, E2F3 has been shown to be another direct target of miR-34a (Welch et al., 2007) , and E2F family members can directly regulate MYCN transcriptionally The underlined sequences on MYCN 3 0 -UTR were mutated to make luciferase reporter constructs containing a single miR-34a binding mutation (pMIR-MYCN-MT1 or MT2) or a double mutation (pMIR-MYCN-MT1&2). The underlined italicized letters (GGCAGUG) in miR-34a denote the seed sequence of miR-34a (positions 2-8 at the 5 0 -end) (Lim et al., 2005) . (c) Luciferase activity assays demonstrated that miR-34a directly suppresses MYCN by targeting the MYCN 3 0 -UTR. Luciferase reporter constructs containing full-length wild-type (WT) and mutant (MT1, MT2 and MT1&2) 3 0 -UTR of MYCN were introduced into SK-N-AS cells with microRNAs, and luciferase activity was measured at 24 h after transfection. Mutation of either miR-34a binding sites (MT1 or MT2) resulted in a reduction of suppression of luciferase activities, whereas double mutation (MT1&2) totally abolished the suppression by miR-34a.
The MYCN oncogene is a direct target of miR-34a JS Wei et al (Strieder and Lutz, 2003) . Thus, miR-34a can modulate MYCN expression at multiple levels. Although this study clearly demonstrated that overexpression of miR34a can efficiently reduce the MYCN protein level, however, to what extent that MYCN protein level is regulated by the endogenous miR-34a is unclear at this point. Data from this study, as well as others showed that miR-34a is expressed in MYCN-amplified tumor but at a lower level (Welch et al., 2007) . These results, together with the observation that MYCN amplification is almost always associated with the 1p36 loss (Maris et al., 2000; Attiyeh et al., 2005) , raise the possibility that haploinsufficiency of miR-34a may contribute to the development of this type of NB, similar to CHD5 and CDC42 in the literatures (Valentijn et al., 2005; Bagchi et al., 2007) . Recently, it has been discovered that p53 directly controls the expression level of the members of miR-34 family, and miR-34 family members can mediate some of the functions of p53 (Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 2007) . Intriguingly, despite of 50% of all human cancers harboring mutations inactivating p53, TP53 mutation is rare in NB (Vogan et al., 1993; Hosoi et al., 1994) . Therefore, we speculate that the reduction of miR-34a expression from loss of 1p36 has a similar consequence to p53 deficiency, which results in increased cell growth and suppression of apoptosis as seen in MYCNamplified NBs. Our study has provided evidence that MYCN is a direct target of miR-34a, which is contrary to a previous study by Welch et al. (2007) . These discrepant results may be due to the differences in the 3 0 -UTRs of the CDC7  CCNB1  CDKN1B  CHEK1  ATM  MCM5  CDC20  MCM6  CDK6  ORC5L  ORC1L  E2F3  PTTG3  MAD2L1  CDK4  MCM3  GSK3B  PTTG1  CDC2  E2F6  E2F5  MCM4  HDAC8  CDC25C  HDAC1  CCNA2  CDC25A  ORC2L  CHEK2  CCNE2  TP53 Down-regulated by miR-34a DNA_REPLICATION_REACTOME RNA_TRANSCRIPTION_REACTOME MRNA_PROCESSING_REACTOME CELL_CYCLE CELL_CYCLE_KEGG G1_TO_S_CELL_CYCLE_REACTOME TRANSLATION_FACTORS
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Up-regulated by miR-34a Figure 4 (a) Summary of gene set enrichment analysis (GSEA) analysis. GSEA analysis was performed on the ranked genes according to the ratios of transcripts from mimic control and miR-34a-transfected IMR32 cells at 48 h. Nine gene sets with a P-value of o0.01 and a false discovery rate (FDR) of o0.05 were considered significant. Of the nine gene sets, seven associate with the downregulated genes by miR-34a, and two sets associate with upregulated genes. (b) One of the GSEA plots indicates significant enrichment of cellcycle genes in the transcripts suppressed by miR-34a (Po0.001 and FDR ¼ 0.007). Affymetrix U133 Plus 2 data for the duplicated experiments of IMR32 cells transfected with miR-34a and mimic control at 48 h transfection were combined, and multiple probe sets for the same genes were averaged. Genes were ordered in their ranked ratios, and GSEAs were performed using the GSEA tool at http://www.broad.mit.edu/gsea. Plot (the green curve) shows the running sum of enrichment score (ES) for ranked genes comparing with the CELL_CYCLE gene set. Red vertical line specifies the maximum ES score. Heat map shows the log2 ratio (miR-34a vs control) of leading edge subset genes in their ranked order, which contribute to the significance. A scale of the log2 ratios is shown on the right. Black lines indicate gene hits in the CELL_CYCLE gene set and the black arrowhead indicates where the log2 ratio ¼ 0.
MYCN gene used in the two studies. We used a native full-length MYCN 3 0 -UTR (B1.3 kb) containing two miR-34a binding sequences, whereas an oligonucleotide or a shorter version of MYCN 3 0 -UTR (625 bp) containing only one of the miR-34a binding sites (binding site 1 in Figure 3b) were used in the other study. We further demonstrated that a double mutation of the miR-34a binding sites in the MYCN 3 0 -UTR completely abolished the suppression of luciferase activity by miR-34a. Therefore, both the miR-34a binding sites are required for an efficient suppression of MYCN by miR-34a. In addition, we have shown that miR-34a inhibited MYCN protein expression by >80% using western blotting in two MYCN-amplified cell lines.
In conclusion, we have demonstrated an important role of miR-34a; a small noncoding microRNA in 1p36 region exerting potential tumor suppressor effects through direct modulation of MYCN protein levels as well as through the suppression of multiple other genes and pathways not directly related to MYCN.
Materials and methods
Cell culture, cell growth, cell viability, apoptosis and BrdU incorporation assay IMR32 and LA-N-5, both with MYCN amplification, were cultured in EMEM media (Quality Biological, Gaithersburg, MD, USA). SK-N-AS and MYCN-3, a NB cell line with an inducible MYCN gene construct (Slack et al., 2005) were maintained in RPMI 1640 media. All media were supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 1% glutamine and 1% P/S (Quality Biological, Gaithersburg, MD, USA), and cells were cultured at 37 1C.
Synthetic microRNAs (160 fmol) were transfected into 1 Â 10 6 IMR32 or LA-N-5 cells using an Amaxa Nucleofector kit according to the manufacture's instruction (Amaxa Biosystems, Cologne, Germany). All synthetic miRIDIAN microRNAs were purchased from Dharmacon Technologies (Lafayette, CO, USA). Cell growth was monitored using the WST-1 assays (Roche Diagnostic GmbH, Mannheim, Germany) for 96 h post-transfection. Cell viability, apoptosis and BrdU incorporation were measured 48 h after transfection using flow cytometry. Cell viability was monitored by staining cells with 7-AAD (BD Biosciences, San Jose, CA, USA), as described elsewhere (Wei et al., 2005) . Apoptosis was measured by immunostaining cells using an antibody specific to the active form of caspase 3 (BD Biosciences). DNA synthesis was measured by BrdU incorporation using a commercially available BrdU immunostaining kit (BD Biosciences) according to the manufacturer's instructions.
Luciferase reporter constructs, site-directed mutagenesis and luciferase reporter assay We cloned the full-length 3 0 -UTR of the MYCN gene into the pMIR-REPORT miRNA expression vector (Ambion, Austin, TX, USA) between SacI and Mlu1 restriction sites using a directional reverse transcription (RT)-PCR cloning strategy (forward primer: GCCGAGCTCCCACCAGCAGCACAAC TATG; reverse primer: GCGACGCGTTAATACGACTCA CTATAGGGAGGCGG). The resulting plasmid, pMIR-MY CN-WT, containing the wild-type 3 0 -UTR of the MYCN gene was sequenced to ensure accuracy.
To ablate the two miR-34a binding sites in the pMIR-MYCN-WT construct (Figure 3c ), we used a QuikChange XL site-direct mutagenesis kit (Stratagene, La Jolla, CA, USA) to generate a mutation on one of the two predicted miR-34a binding sites (pMIR-MYCN-MT1&2) or on both sites (pMIR-MYCN-MT1 & 2) of the MYCN 3 0 -UTR according to the manufacturer's instruction. All three mutation constructs were sequenced to ensure sequence accuracy.
For luciferase assays, we used Dharmafect 1 (Dharmacon Technologies) to co-transfect SK-N-AS cells with luciferase reporter construct plasmids, a b-galactosidase control plasmid and microRNAs (10 nM) per well in 48-well cell culture plates according to the manufacture's instruction. Luciferase activity was measured using a Dual light Luciferase and b-Galactosidase Reporter Gene Assay System (Applied Biosystems, Foster City, CA, USA) at 24 h after transfection. Luciferase activity was then normalized by the b-galactosidase activity for transfection in each well.
RNA extraction and TaqMan real-time PCR RNA extraction was previously described (Wei and Khan, 2002) with modification. In brief, cells or tissues were homogenized in TRIzol solution and larger RNA (>200 nt) was purified by RNeasy columns (Qiagen, Valencia, CA, USA). Ethanol (1.4 volume of the flow through) was added to the flow through of the RNeasy columns to achieve a final concentration of 70%. Then, small size RNA (o200 nt) containing microRNAs (enriched small RNA) was recovered and purified using an Invitrogen PureLink miRNA isolation kit according to the manufacture's instruction (Invitrogen, Carlsbad, CA, USA).
MicroRNA expression was measured using a TaqMan MicroRNA RT-PCR assay (Applied Biosystems) according to the manufacturer's protocol, and microRNA expression levels were normalized against RNU6B expression. We used the Wilcoxon's rank test to calculate the P-value.
Western blotting
Total proteins were extracted from the cells using radioimmuno precipitation assay buffer with 3% proteinase inhibitor cocktail (Sigma, St. Louis, MO, USA). Twenty micrograms of protein (5 mg for the MYCN induction experiment) was separated on a polyacrylamide gel under denaturing conditions and transferred to a nitrocellulose membrane (Invitrogen). The membranes were blocked for 1 h at room temperature, and then incubated overnight at 4 1C in Tris-buffered saline Tween-20 (TBST) containing 5% bovine serum albumin (BSA) and following antibodies: MYCN (OP13; Calbiochem, San Diego, CA, USA); GAPDH (MAB374; Chemicon, Temecula, CA, USA); actin (Sigma). Membranes were washed three times in TBST, and incubated with a secondary antibody conjugated with horseradish peroxidase (Rockland Immunochemicals, Gilbertsville, PA, USA) in TBST and 0.5% BSA for 1 h at room temperature. After two washes with TBS, bands were detected by chemiluminescence using a SuperSignal Chemiluminescence kit (Pierce, Rockford, IL, USA) on Biomax MR X-ray film (Kodak, Rochester, NY, USA). Intensity of the bands was determined using ImageQuant software (GE Healthcare, Piscataway, NJ, USA) in the volume mode.
Gene expression analysis Gene expression profiling was performed using Affymetrix U133 Plus 2.0. arrays for miR-34a transfection experiments; or on Affymetrix U133 AB arrays for MYCN induction experiment, according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA). Gene expression data were normalized using DNA Chip Analyzer (dChip) in the PM-only model (Li and Wong, 2001 ). We used mean intensity X200 to remove probe sets of low quality. Genes suppressed by miR-34a were identified by comparing the miR-34a-transfected IMR32 cells to the mimic control transfected cells at 48 h post-transfection. We used the average of two replicate experiments at this time point. Genes induced by MYCN were identified by comparing expression profiles of MYCN-3 cells at 12 h after MYCN induction with the noninduced control MYCN-3 cells. A threshold of 33% deviation from a ratio ¼ 1 compared to each control was used to select for differentially expressed genes. Affymetrix probes were mapped to Ensembl gene identifiers using the Bioconductor biomaRt package (Durinck et al., 2005) . Probes that mapped to none or more than one Ensembl gene identifier by Ensembl were removed from the analysis. Data from different probes that are mapped to the same Ensembl gene identifier were averaged.
Pathway analysis
In order to investigate the global effect of miR-34a on NB cells, we used GSEA at http://www.broad. mit.edu/gsea for the pathway analysis (Subramanian et al., 2005) on the gene expression profiling data of IMR32 cells transfected with miR34a. Intensities of signals for every probe set from two duplicated experiments were averaged. A total of 35 830 probe sets passed the quality filtering, and they represent 16 782 known genes by the symbol identifier in the GSEA. The ratios of mimic control vs miR-34a were calculated for every probe set, and the mean of ratios from all probe sets was used for genes with multiple probe sets. Genes were ranked using the log2 ratio, and a total of 404 gene sets from a collection of curated biological function databases (http://www.broad.mit. edu/gsea/msigdb/msigdb_index.html) including BioCarta (http://www.biocarta.com/), GenMAPP (http://www.genmapp. org/) and GO (http://www.geneontology.org/), were used in this analysis. After a minimal size of 25 overlapping genes per pathway was applied, 80 gene sets remained. Because of the limited number of samples, we performed a gene set type permutation test. Gene sets with a P-value of o0.01 and a false discovery rate (FDR) of o0.05 were considered significant.
Analysis of enrichment of miR-34a binding and E-box sequences
We first retrieved the 3 0 -UTR sequences of all genes represented on Affymetrix U133 chips as annotated by Ensembl using the biomaRt package (Durinck et al., 2005) . When multiple 3 0 -UTRs were annotated to the same gene, the longest 3 0 -UTR was used. Next, the number of genes that have at least one perfect complementary match to the miR-34a microRNA seed sequence (GGCAGUG) and the number of genes without any complementary seed match were counted. We defined the seed sequence as 2-8 nucleotides from 5 0 -end of miR-34a (Lim et al., 2005) . We repeated this process for the different gene groups displayed in the Venn diagram (Figure 5b) . Finally, we computed P-values for overrepresentation of sequence complementary to miR-34a seed sequence using the counts in a hypergeometric test. To calculate the enrichment of the E-box motifs in the promoter of genes, we retrieved 2.5 kb sequences upstream of the annotated start site of the coding region for each gene, and used the same method to calculate the P-values. Sequences of the E-box motif were published in a previous study (Blackwell et al., 1993) .
